Endoluminal radiofrequency ablation in patients with malignant biliary obstruction: a randomised trial

Gut. 2023 Nov 24;72(12):2286-2293. doi: 10.1136/gutjnl-2023-329700.

Abstract

Background: Endoluminal radiofrequency ablation (RFA) has been promoted as palliative treatment for patients with cholangiocarcinoma (CCA) and pancreatic ductal adenocarcinoma (PDAC) in order to improve biliary drainage and eventually prolong survival. No high level evidence is, however, available on this technique.

Design: In this randomised controlled study, we compared endoluminal RFA plus stenting with stenting alone (control group) in patients with malignant biliary obstruction; metal stents were primarily placed. Primary outcome was overall survival; secondary outcomes were stent patency, quality of life and adverse events. In a superiority design, survival was assumed to be doubled by RFA as compared with 6.4 months in the control group (n=280).

Results: A total of 161 patients (male:female 90:71, mean age 71±9 years) were randomised before recruitment was terminated for futility after an interim analysis. Eighty-five patients had CCA (73 hilar, 12 distal) and 76 had pancreatic cancer. There was no difference in survival in both subgroups: for patients with CCA, median survival was 10.5 months (95% CI 6.7 to 18.3) in the RFA group vs 10.6 months (95% CI 9.0 to 24.8), p=0.58)) in the control group. In the subgroup with pancreatic cancer, median survival was 6.4 months (95% CI 4.3 to 9.7) for the RFA vs 7.7 months (95% CI 5.6 to 11.3), p=0.73) for the control group. No benefit was seen in the RFA group with regard to stent patency (at 12 months 40% vs 36% in CCA and 66% vs 65% in PDAC), and quality of life was unchanged by either treatment and comparable between the groups. Adverse events occurred in seven patients in each groups.

Conclusion: A combination of endoluminal RFA and stenting was not superior to stenting alone in prolonging survival or improving stent patency in patients with malignant biliary obstruction.

Trial registration number: NCT03166436.

Keywords: biliary obstruction; cholangiocarcinoma; pancreatic cancer; stents.

Publication types

  • Randomized Controlled Trial

MeSH terms

  • Aged
  • Aged, 80 and over
  • Bile Duct Neoplasms* / complications
  • Bile Duct Neoplasms* / surgery
  • Bile Ducts, Intrahepatic / surgery
  • Catheter Ablation* / adverse effects
  • Catheter Ablation* / methods
  • Cholangiocarcinoma*
  • Cholestasis* / etiology
  • Cholestasis* / surgery
  • Female
  • Humans
  • Male
  • Middle Aged
  • Pancreatic Neoplasms* / complications
  • Pancreatic Neoplasms* / surgery
  • Quality of Life
  • Radiofrequency Ablation*
  • Stents / adverse effects
  • Treatment Outcome

Associated data

  • ClinicalTrials.gov/NCT03166436